The German pharma and technology company said in a statement that earnings before interest, taxes, depreciation and ...

a jump of 11.8% and ahead of an average analyst estimate of 1.55 billion euros in a consensus posted on the company’s website ...

Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) Statistically significant and clinically ...

The collaboration with Merck KGaA, Darmstadt, Germany focuses on discovering ... A live webcast of the presentation will be ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

- European equities are up, yields flat and seeing a firmer US dollar as sentiment unchanged from yesterday, with higher ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

DELRAY BEACH, Fla., Nov. 11, 2024 /PRNewswire/ -- The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a significant CAGR of 20.6% ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...